查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930126

基因治疗市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察，2026-2034 年

Gene Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

基因治疗市场成长驱动因子

由于遗传科学的快速发展以及罕见疾病和遗传疾病的日益增多，全球基因治疗市场正经历强劲的成长势头。根据 Fortune Business Insights 的数据显示，2025 年基因治疗市场规模为 42.9 亿美元。预计该市场将从 2026 年的 52 亿美元成长到 2034 年的 113.3 亿美元，预测期内复合年增长率 (CAGR) 为 10.20%。北美地区在 2025 年将以 24.60% 的市占率领先，这得益于其强大的研究经费和早期监管审批。

基因治疗是一种透过矫正或取代缺陷基因来治疗或预防疾病的治疗方法。这种疗法正越来越多地用于治疗先天性遗传疾病，例如脊髓性肌肉萎缩症、血友病、地中海贫血B和遗传性视网膜疾病，以及后天性疾病，例如白血病。全球遗传性疾病和罕见疾病负担的日益加重，显着推动了对治疗的需求，并支撑着市场成长。

市场动态

市场驱动因素

全球遗传性疾病的日益增加是基因治疗市场的主要驱动因素。人们对针对疾病根本原因的基因疗法的认识不断提高，促进了其临床应用。根据世界血友病联盟预测，到2023年，全球血友病患病人数预计将达到218,804人，凸显了长期治疗计画的迫切需求。罕见疾病治疗研究活动的增加和资金的投入，进一步加速了市场扩张。

市场限制因子

基因疗法的高昂成本仍是限制患者获得治疗的主要障碍。这些疗法通常涉及复杂的生产过程和单剂量治疗模式，导致价格高昂。例如，2022年12月，CSL公司获得美国FDA批准，其首个用于治疗B型血友病的基因疗法，每次治疗费用高达350万美元。如此高昂的价格给患者、医疗服务提供者和支付方都带来了经济压力，阻碍了基因疗法的广泛应用。

市场机会

基因递送系统的进步带来了巨大的成长机会。旨在提高载体效率、组织特异性和可扩展性的创新正在改变疗法的开发。 2025年5月，Dyno Therapeutics公司推出了一种新型腺相关病毒（AAV）衣壳载体，针对眼部、肌肉骨骼系统和中枢神经系统。预计这些进步将在预测期内促进治疗效果的改善和市场扩张。

市场挑战

基因治疗市场面临的一项关键挑战是维持长期临床疗效。儘管初始治疗反应通常很强劲，但由于免疫反应和转基因表达的减弱，人们仍然担忧疗效的持久性。这需要长期的临床随访，并增加了研发成本。监管机构对疗效持久性的审查也会延迟审批，并影响市场成长。

市场趋势

基因治疗市场的一个显着趋势是专注于提高生产规模化能力。随着临床候选药物的增加，各公司正在投资先进的生物加工技术和自动化生产系统。 2024年10月，细胞和基因治疗加速器（Cell and Gene Therapy Catapult）筹集了150万美元，用于降低腺相关病毒（AAV）的生产成本并提高规模化能力。这反映了整个产业为加强供应能力所做的努力。

市场区隔分析

依产品划分

市场细分为 Zolgensma、Luxturna、Roctavian 等产品。

预计 Zolgensma 将在 2024 年占市场主导地位，并在 2025 年达到 12.4 亿美元的市场规模，这主要得益于其在治疗脊髓性肌肉萎缩症方面久经考验的持久性和有效性。

预计 Roctavian 市场在预测期内将以 38.72% 的复合年增长率成长。

依载体型别划分

病毒载体凭藉其高转导效率和持续的基因表达，在 2026 年占市场主导地位，市占率高达 98.46%。非病毒载体市场预计将以 57.65% 的复合年增长率成长。

依适应症划分

2024年，遗传性疾病领域占最大市场占有率，预计到2025年将占31.4%，这主要得益于对个人化治疗需求的不断增长。眼科领域预计将以19.35%的复合年增长率成长。

依最终使用者划分

医院和诊所领域在2025年占主导地位，市占率达55.99%，主要得益于其在临床检测和治疗服务中所扮演的角色。

区域展望

北美地区保持领先地位，预计2025年市场规模将达到10.5亿美元，2026年将达到11.2亿美元，主要得益于积极的研发活动和FDA的批准。

在有利的监管框架支持下，欧洲预计到 2025 年将达到 23.2 亿美元。

亚太地区预计到 2026 年将达到 5.3 亿美元，而印度和中国将分别达到 4,000 万美元和 1.9 亿美元。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 基因疗法新适应症的开发
  • 主要国家和地区的监管环境
  • 基因治疗市场的技术进步
  • 主要公司的新产品发布
  • 主要公司的研发管线分析
  • 主要产业趋势（併购、合作、产品发表）等等）
  • 基因治疗市场定价与报销趋势
  • 生产与供应链洞察
  • 市场投资与融资趋势
  • 患者获得治疗的机会与伦理考量

第五章 全球基因治疗市场分析、洞察与预测（2021-2034）

  • 市场分析、洞察与预测 - 按产品分类
    • Zolgensma
    • Luxturna
    • Locavian
    • 其他
  • 市场分析、洞察与预测 - 按载体类型分类
    • 病毒载体
    • 非病毒载体
  • 市场分析、洞察与预测 - 按适应症分类
    • 基因疾病
    • 眼科
    • 血液科
    • 其他
  • 市场分析、洞察与预测 - 按最终用户划分
    • 医院和诊所
    • 专科诊所
    • 其他
  • 市场分析、洞察与预测 - 按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美基因治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲基因治疗市场分析、洞察与预测2021-2034

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章 亚太地区基因治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲基因治疗市场分析、洞察与预测（2021-2034）

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东和非洲基因治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
  • 诺华公司
  • F.罗氏製药股份有限公司
  • BioMarin製药公司
  • CSL
  • Vertex製药公司
  • Krystal BIoTech公司
  • Rocket製药公司
  • Dyno Therapeutics公司
Product Code: FBI100243

Growth Factors of gene therapy Market

The global gene therapy market is experiencing strong momentum due to rapid advancements in genetic science and the increasing prevalence of rare and inherited disorders. According to Fortune Business Insights, the gene therapy market was valued at USD 4.29 billion in 2025. The market is projected to grow from USD 5.20 billion in 2026 to USD 11.33 billion by 2034, registering a CAGR of 10.20% during the forecast period. In 2025, North America dominated the market with a share of 24.60%, supported by strong research funding and early regulatory approvals.

Gene therapy involves modifying or replacing defective genes to treat or prevent diseases. These therapies are increasingly used for congenital genetic disorders such as spinal muscular atrophy, hemophilia, B-thalassemia, and inherited retinal diseases, as well as acquired conditions such as leukemia. The rising global burden of genetic and rare diseases is significantly driving demand for curative therapies, thereby supporting market growth.

Market Dynamics

Market Drivers

The rising burden of genetic disorders worldwide is a key driver of the gene therapy market. The growing awareness of gene-based treatments that address the root cause of diseases has increased clinical adoption. According to the World Federation of Hemophilia, 218,804 hemophilia patients were reported globally in 2023, highlighting the unmet need for long-term therapeutic solutions. Increasing research activities and funding for rare disease treatment further accelerate market expansion.

Market Restraints

The high cost of gene therapies remains a major restraint limiting patient access. These therapies often involve complex manufacturing processes and one-time treatment models, resulting in extremely high prices. For instance, in December 2022, CSL received U.S. FDA approval for the first gene therapy for hemophilia B, priced at USD 3.5 million per treatment. Such pricing creates financial challenges for patients, healthcare providers, and payers, slowing widespread adoption.

Market Opportunities

Advancements in gene delivery systems present significant growth opportunities. Innovations aimed at improving vector efficiency, tissue specificity, and scalability are transforming therapy development. In May 2025, Dyno Therapeutics launched new adeno-associated virus (AAV) capsid vectors targeting the eye, musculoskeletal system, and central nervous system. These developments are expected to improve therapeutic outcomes and support market expansion during the forecast period.

Market Challenges

A key challenge in the gene therapy market is maintaining long-term clinical efficacy. While early treatment responses are often strong, durability concerns remain due to immune responses and declining transgene expression. This necessitates extended clinical follow-up and increases development costs. Regulatory scrutiny regarding durability has also delayed approvals, impacting market growth.

Market Trends

A prominent trend in the gene therapy market is the focus on improving manufacturing scalability. With the growing number of clinical candidates, companies are investing in advanced bioprocessing technologies and automated manufacturing systems. In October 2024, the Cell and Gene Therapy Catapult received USD 1.5 million in funding to reduce AAV production costs and improve scalability, reflecting industry-wide efforts to enhance supply capabilities.

Segmentation Analysis

By Product

The market is segmented into Zolgensma, Luxturna, Roctavian, and others.

The Zolgensma segment dominated the market in 2024, with a value of USD 1.24 billion in 2025, driven by its proven durability and effectiveness in treating spinal muscular atrophy.

The Roctavian segment is projected to grow at a CAGR of 38.72% over the forecast period.

By Vector Type

Viral vectors dominated the market, accounting for 98.46% share in 2026, due to high transduction efficiency and long-lasting gene expression. The non-viral vector segment is expected to grow at a CAGR of 57.65%.

By Indication

The genetic disorders segment held the largest share in 2024 and is expected to account for 31.4% of the market in 2025, driven by increasing demand for personalized therapies. The ophthalmology segment is projected to grow at a CAGR of 19.35%.

By End User

The hospitals & clinics segment dominated the market with a 55.99% share in 2025, supported by their role in clinical trials and treatment administration.

Regional Outlook

North America led the market with a value of USD 1.05 billion in 2025 and USD 1.12 billion in 2026, driven by strong R&D activity and FDA approvals.

Europe reached USD 2.32 billion in 2025, supported by favorable regulatory frameworks.

Asia Pacific recorded USD 0.53 billion in 2026, with India and China valued at USD 0.04 billion and USD 0.19 billion, respectively.

Competitive Landscape

The market is semi-consolidated, led by Novartis AG, F. Hoffmann-La Roche Ltd., and BioMarin Pharmaceutical Inc. These companies benefit from strong product portfolios, global reach, and active R&D pipelines. Other key players include CSL, Vertex Pharmaceuticals, Krystal Biotech, and Rocket Pharmaceuticals.

Conclusion

The global gene therapy market is set for sustained growth from USD 4.29 billion in 2025 to USD 11.33 billion by 2034, driven by rising genetic disease prevalence, technological advancements, and increasing regulatory approvals. Despite challenges related to cost and long-term efficacy, continued innovation in delivery systems and manufacturing scalability is expected to support long-term market expansion.

Segmentation By Product

  • Zolgensma
  • Luxturna
  • Roctavian
  • Others

By Vector Product

  • Viral Vectors
  • Non-Viral Vectors

By Indication

  • Genetic Disorders
  • Ophthalmology
  • Hematology
  • Others

By End User

  • Hospitals & Clinics
  • Specialty Clinics
  • Others

By Geography

  • North America (By Product, Vector Type, Indication, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Product, Vector Type, Indication, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Vector Type, Indication, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Vector Type, Indication, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Vector Type, Indication, End User, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Development of Gene Therapy for New Disease Indications
  • 4.2. Regulatory Scenarios, By Key Countries/Regions
  • 4.3. Technological Advancements in Gene Therapy Market
  • 4.4. New Product Launches, By Key Players
  • 4.5. Pipeline Analysis, By Key Companies
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)
  • 4.7. Pricing & Reimbursement Landscape in the Gene Therapy Market
  • 4.8. Manufacturing & Supply Chain Insights
  • 4.9. Investment & Funding Trends in the Market
  • 4.10. Patient Access to the Therapy & Ethical Considerations

5. Global Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Zolgensma
    • 5.1.2. Luxturna
    • 5.1.3. Roctavian
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Vector Type
    • 5.2.1. Viral Vectors
    • 5.2.2. Non-Viral Vectors
  • 5.3. Market Analysis, Insights and Forecast - By Indication
    • 5.3.1. Genetic Disorders
    • 5.3.2. Ophthalmology
    • 5.3.3. Hematology
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Hospitals & Clinics
    • 5.4.2. Specialty Clinics
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Zolgensma
    • 6.1.2. Luxturna
    • 6.1.3. Roctavian
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Vector Type
    • 6.2.1. Viral Vectors
    • 6.2.2. Non-Viral Vectors
  • 6.3. Market Analysis, Insights and Forecast - By Indication
    • 6.3.1. Genetic Disorders
    • 6.3.2. Ophthalmology
    • 6.3.3. Hematology
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Hospitals & Clinics
    • 6.4.2. Specialty Clinics
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Zolgensma
    • 7.1.2. Luxturna
    • 7.1.3. Roctavian
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Vector Type
    • 7.2.1. Viral Vectors
    • 7.2.2. Non-Viral Vectors
  • 7.3. Market Analysis, Insights and Forecast - By Indication
    • 7.3.1. Genetic Disorders
    • 7.3.2. Ophthalmology
    • 7.3.3. Hematology
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Hospitals & Clinics
    • 7.4.2. Specialty Clinics
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Zolgensma
    • 8.1.2. Luxturna
    • 8.1.3. Roctavian
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Vector Type
    • 8.2.1. Viral Vectors
    • 8.2.2. Non-Viral Vectors
  • 8.3. Market Analysis, Insights and Forecast - By Indication
    • 8.3.1. Genetic Disorders
    • 8.3.2. Ophthalmology
    • 8.3.3. Hematology
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Hospitals & Clinics
    • 8.4.2. Specialty Clinics
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Zolgensma
    • 9.1.2. Luxturna
    • 9.1.3. Roctavian
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Vector Type
    • 9.2.1. Viral Vectors
    • 9.2.2. Non-Viral Vectors
  • 9.3. Market Analysis, Insights and Forecast - By Indication
    • 9.3.1. Genetic Disorders
    • 9.3.2. Ophthalmology
    • 9.3.3. Hematology
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Hospitals & Clinics
    • 9.4.2. Specialty Clinics
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Zolgensma
    • 10.1.2. Luxturna
    • 10.1.3. Roctavian
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Vector Type
    • 10.2.1. Viral Vectors
    • 10.2.2. Non-Viral Vectors
  • 10.3. Market Analysis, Insights and Forecast - By Indication
    • 10.3.1. Genetic Disorders
    • 10.3.2. Ophthalmology
    • 10.3.3. Hematology
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Hospitals & Clinics
    • 10.4.2. Specialty Clinics
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of the Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. Novartis AG
    • 11.2.2. F. Hoffmann-La Roche Ltd
    • 11.2.3. BioMarin Pharmaceutical Inc.
    • 11.2.4. CSL
    • 11.2.5. Vertex Pharmaceuticals Incorporated
    • 11.2.6. Krystal Biotech, Inc.
    • 11.2.7. Rocket Pharmaceuticals
    • 11.2.8. Dyno Therapeutics, Inc.

List of Tables

  • Table 1: Global Gene Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 2: Global Gene Therapy Market Revenue (USD Billion) Forecast, By Vector Type, 2021-2034
  • Table 3: Global Gene Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 4: Global Gene Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 5: Global Gene Therapy Market Revenue (USD Billion) Forecast, by Region, 2021-2034
  • Table 6: North America Gene Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 7: North America Gene Therapy Market Revenue (USD Billion) Forecast, By Vector Type, 2021-2034
  • Table 8: North America Gene Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 9: North America Gene Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 10: North America Gene Therapy Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Gene Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 12: Europe Gene Therapy Market Revenue (USD Billion) Forecast, By Vector Type, 2021-2034
  • Table 13: Europe Gene Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 14: Europe Gene Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 15: Europe Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Gene Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 17: Asia Pacific Gene Therapy Market Revenue (USD Billion) Forecast, By Vector Type, 2021-2034
  • Table 18: Asia Pacific Gene Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 19: Asia Pacific Gene Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 20: Asia Pacific Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Gene Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 22: Latin America Gene Therapy Market Revenue (USD Billion) Forecast, By Vector Type, 2021-2034
  • Table 23: Latin America Gene Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 24: Latin America Gene Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 25: Latin America Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Gene Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 27: Middle East & Africa Gene Therapy Market Revenue (USD Billion) Forecast, By Vector Type, 2021-2034
  • Table 28: Middle East & Africa Gene Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 29: Middle East & Africa Gene Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 30: Middle East & Africa Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Gene Therapy Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 2: Global Gene Therapy Market Value Share (%), By Product, 2025 & 2034
  • Figure 3: Global Gene Therapy Market Value Share (%), By Vector Type, 2025 & 2034
  • Figure 4: Global Gene Therapy Market Value Share (%), By Indication, 2025 & 2034
  • Figure 5: Global Gene Therapy Market Value Share (%), By End User, 2025 & 2034
  • Figure 6: Global Gene Therapy Market Value (USD Billion), by Region, 2025 & 2034
  • Figure 7: North America Gene Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 8: North America Gene Therapy Market Value Share (%), By Product, 2025
  • Figure 9: North America Gene Therapy Market Value (USD Billion), By Vector Type, 2025 & 2034
  • Figure 10: North America Gene Therapy Market Value Share (%), By Vector Type, 2025
  • Figure 11: North America Gene Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 12: North America Gene Therapy Market Value Share (%), By Indication, 2025
  • Figure 13: North America Gene Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 14: North America Gene Therapy Market Value Share (%), By End User, 2025
  • Figure 15: North America Gene Therapy Market Value (USD Billion), By Country, 2025 & 2034
  • Figure 16: North America Gene Therapy Market Value Share (%), By Country, 2025
  • Figure 17: Europe Gene Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 18: Europe Gene Therapy Market Value Share (%), By Product, 2025
  • Figure 19: Europe Gene Therapy Market Value (USD Billion), By Vector Type, 2025 & 2034
  • Figure 20: Europe Gene Therapy Market Value Share (%), By Vector Type, 2025
  • Figure 21: Europe Gene Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 22: Europe Gene Therapy Market Value Share (%), By Indication, 2025
  • Figure 23: Europe Gene Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 24: Europe Gene Therapy Market Value Share (%), By End User, 2025
  • Figure 25: Europe Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Gene Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 28: Asia Pacific Gene Therapy Market Value Share (%), By Product, 2025
  • Figure 29: Asia Pacific Gene Therapy Market Value (USD Billion), By Vector Type, 2025 & 2034
  • Figure 30: Asia Pacific Gene Therapy Market Value Share (%), By Vector Type, 2025
  • Figure 31: Asia Pacific Gene Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 32: Asia Pacific Gene Therapy Market Value Share (%), By Indication, 2025
  • Figure 33: Asia Pacific Gene Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 34: Asia Pacific Gene Therapy Market Value Share (%), By End User, 2025
  • Figure 35: Asia Pacific Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Gene Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 38: Latin America Gene Therapy Market Value Share (%), By Product, 2025
  • Figure 39: Latin America Gene Therapy Market Value (USD Billion), By Vector Type, 2025 & 2034
  • Figure 40: Latin America Gene Therapy Market Value Share (%), By Vector Type, 2025
  • Figure 41: Latin America Gene Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 42: Latin America Gene Therapy Market Value Share (%), By Indication, 2025
  • Figure 43: Latin America Gene Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 44: Latin America Gene Therapy Market Value Share (%), By End User, 2025
  • Figure 45: Latin America Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Gene Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 48: Middle East & Africa Gene Therapy Market Value Share (%), By Product, 2025
  • Figure 49: Middle East & Africa Gene Therapy Market Value (USD Billion), By Vector Type, 2025 & 2034
  • Figure 50: Middle East & Africa Gene Therapy Market Value Share (%), By Vector Type, 2025
  • Figure 51: Middle East & Africa Gene Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 52: Middle East & Africa Gene Therapy Market Value Share (%), By Indication, 2025
  • Figure 53: Middle East & Africa Gene Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 54: Middle East & Africa Gene Therapy Market Value Share (%), By End User, 2025
  • Figure 55: Middle East & Africa Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Gene Therapy Market Share (%), By Company, 2025